Results 71 to 80 of about 160,408 (307)

The Utility of serological markers in inflammatory bowel diseases: Gadget or magic? [PDF]

open access: yes, 2008
The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Anti–Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated ...
Papp, Mária   +3 more
core  

Nano‐Backpack Engineered Probiotics with Reactive Oxygen Species–Responsive Tungsten Release for Synergistic Therapy of Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
An integrated probiotic system is engineered to execute a programmed therapeutic cascade against inflammatory bowel disease. Upon pathological signals, the system sequentially performs ROS scavenging, tungsten release, and selective pathogen suppression, thereby breaking the oxidative stress–dysbiosis cycle to remodel gut microbiota and reinforce ...
Yang Yang   +8 more
wiley   +1 more source

Utility of serological markers in inflammatory bowel diseases: Gadget or magic? [PDF]

open access: yes, 2007
The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely ...
Papp, Mária   +3 more
core  

Whole‐Genome Sequencing Pilot of the Central Asian Genomic Diversity Project Reveals Distinct Histories, Adaptation, and Introgression

open access: yesAdvanced Science, EarlyView.
As a pilot phase of the Central Asian Genomic Diversity Project, whole‐genome sequencing of 166 individuals from 20 Central Asian and Afghan Hazara populations reveals fine‐scale substructure shaped by repeated trans‐Eurasian migration and admixture. Integrated analyses uncover post‐admixture adaptation, archaic introgression, and medically relevant ...
Mengge Wang   +11 more
wiley   +1 more source

Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
An orally administered prebiotic polysaccharide hydrogel (predaGel) based on inulin and alginate‐dopamine is stable in the stomach, adheres to the intestine, and degrades slowly in the colon. It enables site‐specific delivery of anti‐TNF‐α and anti‐IL‐12/23 antibodies, scavenges reactive oxygen species, and remodels gut microbiota, offering effective ...
Xinyi Dong   +4 more
wiley   +1 more source

weswong/IBD-HMM: IBD-HMM

open access: yes, 2016
<p>IBD-HMM used in the manuscript Genetic relatedness analysis reveals the cotransmission of genetically related Plasmodium falciparum parasites in Thies, Senegal.
weswong
core   +1 more source

Risk of Inflammatory Bowel Disease Following Hospital‐Treated Infections and Modulatory Role of Host Genetics to Support a Multi‐Hit Pathogenesis Model

open access: yesAdvanced Science, EarlyView.
Hospital‐treated infections are linked to increased risk of inflammatory bowel disease in a large prospective cohort. This risk differs by infection burden, time since infection, and host immune‐genetic susceptibility. The findings support a multi‐hit pathogenesis model in which severe infection and inherited susceptibility jointly shape inflammatory ...
Haiming Zhuang   +16 more
wiley   +1 more source

Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice [PDF]

open access: yes, 2009
BACKGROUND AND AIM:: By combining QTL and gene expression analyses, we have previously identified Cd14 as a potential candidate gene contributing to the differential IBD susceptibility of C3H/HeJBir (C3/J)-Il10(-/-) mice [carrying IBD-resistance alleles ...
Obermeier, F.   +24 more
core   +1 more source

Additional file 1 of Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

open access: yes, 2022
Additional file 1: Table 1a. TARGET-IBD Labs/Imaging 24 Weeks Prior to Dose Changes of Biologic Therapy Due to Lack of Effect. Table 1b. TARGET-IBD Labs/Imaging 24 Weeks Prior to Discontinuations of Biologic Therapy Due to Lack of Effect.
Marla C. Dubinsky (10978320)   +10 more
core   +1 more source

Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors

open access: yesAdvanced Science, EarlyView.
This study introduces β‐glucan‐shielded apremilast laden nanomicelles that withstand gastrointestinal degradation, selectively accumulate in inflamed colon tissue, and modulate the microbiota–gut–brain axis. The formulation restores barrier integrity, reduces systemic and neuroinflammation, and improves anxiety‐ and depression‐like behaviors in colitis
Chandrashekhar Jori   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy